Abstract:Indoleamine 2,3-dioxygenase 1 (IDO) is a tryptophan (Trp) metabolic enzyme along the kynurenine (NFK) pathway. Under pathological conditions, IDO overexpressed by tumor cells causes depletion of tryptophan and the accumulation of metabolic products, which inhibit the local immune response and form immune escape. Therefore, the suppression of IDO activity is one of the strategies for tumor immunotherapy, and drug design for this target has been the focus of research for more than two decades. Apart from IDO, tryptophan dioxygenase (TDO) of the same family can also catalyze the same biochemical reaction in the human body, but it has different tissue distribution and substrate selectivity from IDO. Based on the principle of drug design with high potency and low cross-reactivity to specific targets, in this subject, the activity and selectivity of IDO and TDO toward small molecular inhibitors were studied from the perspective of thermodynamics and kinetics. The aim was to elucidate the structural requirements for achieving favorable biological activity and selectivity of IDO and TDO inhibitors. Specifically, the interactions of inhibitors from eight families with IDO and TDO were initially investigated through molecular docking and molecular dynamics simulations, and the thermodynamic data for binding of inhibitors were predicted by the molecular mechanics/generalized Born surface area (MM/GBSA) method. Secondly, we explored the free energy landscape of JKloops, the kinetic control element of IDO/TDO, using temperature replica exchange molecular dynamics (T-REMD) simulations and elucidated the connection between the rules of IDO/TDO conformational changes and the inhibitor selectivity mechanism. Furthermore, the binding and dissociation processes of the C1 inhibitor (NLG919) were simulated by the adaptive steering molecular dynamics (ASMD) method, which not only addressed the possible stable, metastable, and transition states for C1 inhibitor-IDO/TDO interactions, but also accurately predicted kinetic data for C1 inhibitor binding and dissociation. In conclusion, we have constructed a complete process from enzyme (IDO/TDO) conformational activation to inhibitor binding/dissociation and used the thermodynamic and kinetic data of each link as clues to verify the control mechanism of IDO/TDO on inhibitor selectivity. This is of great significance for us to understand the design principles of tumor immunotherapy drugs and to avoid drug resistance of immunotherapy drugs.

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors

Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies.

Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies

Discovery of Potent IDO1 Inhibitors Derived from Tryptophan Using Scaffold-Hopping and Structure-Based Design Approaches.

Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays

Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-dione Derivatives As IDO1 Inhibitors

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

Design, Synthesis and Biological Evaluation of Novel Naphthoquinone Derivatives As IDO1 Inhibitors

Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy

A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

Design, synthesis and antitumor activity of icotinib derivatives

Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1

Structure-Activity Relationship and Enzyme Kinetic Studies on 4-Aryl-1h-1,2, 3-Triazoles As Indoleamine 2,3-Dioxygenase (ido) Inhibitors

Design, Synthesis And Biological Evaluation Of Novel 1,2,5-Oxadiazol-3-Carboximidamide Derivatives As Indoleamine 2, 3-Dioxygenase 1 (Ido1) Inhibitors

Discovery of Tryptanthrin Derivatives As Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice.

Inhibitory Investigation of Niacin Derivatives on Metalloenzyme Indoleamine 2,3-Dioxygenase 1 for Its Immunomodulatory Function

Discovery of a potent apo-IDO1 inhibitor for cancer immunotherapy

Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1

A theoretical study on the activity and selectivity of IDO/TDO inhibitors